Clinical trials
catalyst calendar across sponsors →Studies where ARAY is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 3 with posted results
Held by 14 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, JANE STREET GROUP, LLC, RENAISSANCE TECHNOLOGIES LLC, MILLENNIUM MANAGEMENT LLC, Squarepoint Ops LLC, +9 more) · FINRA short interest 3.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy DosimetryNCT00643617results2023-05-09Risk for Gastrointestinal (GI) and Genitourinary (GU) ToxicityOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Radiation: CyberKnife Stereotactic Radiosurgery - Low Risk, CyberKnife Stereotactic Radiosurgery - Intermediate Risk | Prostate Cancer, Prostatic Cancer, Prostatic Neoplasms, Prostate Neoplasms, Cancer of the Prostate | 307 | 2022-04-07actual | 2023-05-09 |
| CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung CancerNCT00643318Local progression-free survival, local disease progression, clinical response rate, regional recurrence-free survival, distant recurrence-free survival.Open-label · Treatment | Phase 2 | Unknown status | Radiation: CyberKnife Stereotactic Radiosurgery | Non-small Cell Lung Cancer | 40 | Dec 2021 | 2021-03-05 |
| CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose DistributionNCT00643994results2023-05-09Risk for Gastrointestinal (GI) and Genitourinary (GU) ToxicityOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Radiation: CyberKnife Stereotactic Radiosurgery | Prostate Cancer, Prostatic Cancer, Prostate Neoplasms, Prostatic Neoplasms, Cancer of the Prostate | 379 | 2021-01-27actual | 2023-05-09 |
| Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)NCT01318200Freedom from local progressionRandomized · Open-label · Treatment | Phase 3 | Withdrawn | Procedure: Transarterial Chemoembolization · Radiation: CyberKnife SBRT | Recurrent Hepatocellular Carcinoma | 0 | Feb 2014 | 2012-02-20 |
| Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung CancerNCT00840749results2020-07-14Overall SurvivalRandomized · Open-label · Treatment | Not applicable | Terminatedsponsor's stated reason: Lack of enrollment | Radiation: CyberKnife Stereotactic Radiotherapy · Procedure: Surgery | Non-small Cell Lung Cancer | 36 | Mar 2013actual | 2020-07-14 |
| CyberKnife® for Hepatic Metastases From Colorectal CancerNCT01318447Local recurrence-free survivalOpen-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Lack of enrollment | Radiation: CyberKnife SBRT | Colorectal Liver Metastases | 15 | Mar 2013actual | 2013-04-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19